Versant Venture Capital VI, L.P. → Aligos Therapeutics, Inc. ALGS

Stake: — Shares: —

Item 4 — Purpose of Transaction

Not extracted from this filing — typically because it's an amendment (13D/A) and Item 4 is unchanged from the parent filing. Read the raw SEC filing →

Cross-References

Insider Activity (last 365d)

0 transactions

0 buys · 0 sales · 0 awards/exercises

Issuer Cluster

1 13D/G filings on this issuer

0 other filings besides this one

Filer Track Record

5 filings by this filer

4 other filings in the data moat

Short Interest · settle 2026-03-31

DTC 7.59

306,176 shares short · +3.8% vs prior

Other Filings by Versant Venture Capital VI, L.P.

Filed	Form	Issuer	Stake	Shares
2026-01-09	SCHEDULE	Monte Rosa Therapeutics, Inc. GLUE	3.40%	2,236,708	view →
2025-02-11	SCHEDULE	Tempest Therapeutics, Inc. TPST	4.80%	2,118,644	view →
2021-05-24	SC	Oyster Point Pharma, Inc.	—	—	view →
2021-04-05	SC	Oyster Point Pharma, Inc.	—	—	view →

Want this depth on every filing the moment it hits SEC EDGAR?

Full feed access · API · daily intelligence brief · custom alerts. $1,500/mo. Pilots welcome.

Request a pilot →